Amer Zeidan: Our newest paper on 61 TP53-mutated AML

Amer Zeidan shared on X:

“Our newest paper with a detailed Integrated analysis of genetic, epigenetic, and immune landscape in 61 TP53-mutated acute myeloid leukemia (AML) and higher risk myelodysplastic syndrome (MDS) treated with azacitidine in a randomized clinical trial and compared to 144 TP53 wild type AML higher-risk MDS (myelodysplastic syndrome) patients.”

Proceed to the article.
Source: Amer Zeidan/X

Amer Zeidan is an Associate Professor of Medicine (Hematology) at Yale University. He is also the medical director of Hematology Early Therapeutics Research, the leader of the Myeloid Malignancies DART (Disease Aligned Research Team), and the director of Continuing Medical Education (CME) at the Hematology division and chairs the Protocol Review Committee (PRC) at Yale Cancer Center.

Dr. Zeidan is a well-known leukemia researcher with a special focus on targeted therapies and immunotherapy for myeloid malignancies, and a social media influencer in the field of blood cancer.